BYSI
BeyondSpring Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.51
−8.28%Year over year
Reported trailing growth
- Revenue
- +100.0%
- EBITDA
- -44.3%
- EBIT
- -41.7%
- EPS
- —
- Free cash flow
- -64.3%
- Operating cash flow
- -65.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -0.6%
- EBIT
- -2.2%
- Net income
- +28.1%
- EPS
- +28.6%
- Free cash flow
- -20.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026